178.95
1.46 (0.82%)
Previous Close | 177.49 |
Open | 179.83 |
Volume | 1,028,825 |
Avg. Volume (3M) | 2,418,453 |
Market Cap | 30,421,499,904 |
Price / Earnings (TTM) | 25.90 |
Price / Earnings (Forward) | 15.60 |
Price / Sales | 2.33 |
Price / Book | 6.01 |
52 Weeks Range | |
Earnings Date | 22 Jul 2025 |
Profit Margin | 7.88% |
Operating Margin (TTM) | 13.39% |
Diluted EPS (TTM) | 6.89 |
Quarterly Revenue Growth (YOY) | 5.30% |
Quarterly Earnings Growth (YOY) | -26.70% |
Total Debt/Equity (MRQ) | 272.12% |
Current Ratio (MRQ) | 0.840 |
Operating Cash Flow (TTM) | 2.62 B |
Levered Free Cash Flow (TTM) | 2.45 B |
Return on Assets (TTM) | 5.16% |
Return on Equity (TTM) | 19.79% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (US) | Bullish | Mixed |
Diagnostics & Research (Global) | Bullish | Mixed | |
Stock | IQVIA Holdings, Inc. | Bullish | Bearish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 1.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 4.0 |
Average | 2.63 |
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Mid Core |
% Held by Insiders | 1.05% |
% Held by Institutions | 98.21% |
52 Weeks Range | ||
Price Target Range | ||
High | 240.00 (Evercore ISI Group, 34.12%) | Buy |
Median | 225.00 (25.73%) | |
Low | 196.00 (Baird, 9.53%) | Hold |
Average | 222.63 (24.41%) | |
Total | 6 Buy, 2 Hold | |
Avg. Price @ Call | 197.43 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HSBC | 09 Oct 2025 | 235.00 (31.32%) | Buy | 203.00 |
Evercore ISI Group | 08 Oct 2025 | 240.00 (34.12%) | Buy | 200.60 |
Barclays | 02 Oct 2025 | 200.00 (11.76%) | Hold | 204.34 |
23 Jul 2025 | 185.00 (3.38%) | Hold | 194.24 | |
Jefferies | 09 Sep 2025 | 225.00 (25.73%) | Buy | 189.64 |
Mizuho | 25 Jul 2025 | 225.00 (25.73%) | Buy | 199.17 |
Baird | 23 Jul 2025 | 196.00 (9.53%) | Hold | 194.24 |
Truist Securities | 23 Jul 2025 | 235.00 (31.32%) | Buy | 194.24 |
UBS | 23 Jul 2025 | 225.00 (25.73%) | Buy | 194.24 |
No data within this time range.
Date | Type | Details |
---|---|---|
30 Sep 2025 | Announcement | IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 |
16 Sep 2025 | Announcement | IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships |
10 Sep 2025 | Announcement | IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management |
02 Sep 2025 | Announcement | IQVIA Announces CFO Transition in Early 2026 |
28 Aug 2025 | Announcement | IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies |
18 Aug 2025 | Announcement | IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes |
18 Aug 2025 | Announcement | IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes |
22 Jul 2025 | Announcement | IQVIA Reports Second-Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |